FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891929362> ?p ?o ?g. }

• W2891929362 endingPage "11062" @default.
• W2891929362 startingPage "11062" @default.
• W2891929362 abstract "11062 Background: Extraskeletal myxoid chondrosarcoma (EMC) is an exceedingly rare sarcoma, marked by a specific translocation involving the gene NR4A3 that can be rearranged with different partners. Preliminary retrospective data suggest that sunitinib is active, but no formal prospective studies are available. We report on a multicentric European prospective, investigator-driven, Phase 2 study on pazopanib (P) in NR4A3+ advanced EMC patients (pts), carried out by the Spanish, Italian and French Sarcoma groups. Methods: From June 2014 to November 2016, 24 advanced EMC pts entered this study (median age: 64 yrs - disease extent: metastatic 77%, locally advanced 23% - prior medical treatment: 18 (86%) naive; 2 (9%) 1 line, 1 (5%) > 1 line). Path diagnosis and NR4A3 rearrangement (FISH and/or real-time PCR analysis) were centrally confirmed. Pts received P 800 mg/day (relative dose intensity = 0,82%, 658 mg/day), until progression or toxicity. The primary study end-point was response rate as per RECIST 1.1. Secondary end-points were overall survival, progression-free survival (PFS), clinical benefit rate (CBR) (RECIST CR+PR+SD≥6mos). An exploratory evaluation of the correlation between the rearrangement subtype and the outcome is ongoing. Results: 20/24 pts were evaluable for response (1 early death; 3 too early). One patient (5%) had a partial response, 17 (75%) stable disease, 2 (10%) progression as their best RECIST responses. At the time of this analysis, 12 pts were still under treatment, while 12 interrupted P (10 progression, 1 toxicity, 1 other). At a 13-month median follow-up, the median PFS was 13 months (range 1.6-25.1), with 29% pts progression-free at 18 months and a 65% CBR. Median OS was not reached. Conclusions: This Phase 2 study is formally negative since the target of at least 3/21 RECIST responses was not reached. However, looking at PFS, P was associated with a prolonged disease stabilization in a significant proportion of pts. This suggests to further explore the use of P in EMC. Clinical trial information: NCT02066285." @default.
• W2891929362 created "2018-09-27" @default.
• W2891929362 creator A5006074198 @default.
• W2891929362 creator A5013226419 @default.
• W2891929362 creator A5015707436 @default.
• W2891929362 creator A5020559697 @default.
• W2891929362 creator A5020672869 @default.
• W2891929362 creator A5030970489 @default.
• W2891929362 creator A5040082039 @default.
• W2891929362 creator A5040210154 @default.
• W2891929362 creator A5042202815 @default.
• W2891929362 creator A5044250695 @default.
• W2891929362 creator A5049143229 @default.
• W2891929362 creator A5050031420 @default.
• W2891929362 creator A5050932223 @default.
• W2891929362 creator A5053190653 @default.
• W2891929362 creator A5060949051 @default.
• W2891929362 creator A5080548972 @default.
• W2891929362 creator A5081736939 @default.
• W2891929362 creator A5082287639 @default.
• W2891929362 creator A5085410610 @default.
• W2891929362 creator A5086705074 @default.
• W2891929362 date "2017-05-20" @default.
• W2891929362 modified "2023-10-02" @default.
• W2891929362 title "International single-arm phase II trial of pazopanib in advanced extraskeletal myxoid chondrosarcoma: A Collaborative Spanish (GEIS), Italian (ISG) and French (FSG) Sarcoma Groups study." @default.
• W2891929362 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.11062" @default.
• W2891929362 hasPublicationYear "2017" @default.
• W2891929362 type Work @default.
• W2891929362 sameAs 2891929362 @default.
• W2891929362 citedByCount "3" @default.
• W2891929362 countsByYear W28919293622017 @default.
• W2891929362 countsByYear W28919293622018 @default.
• W2891929362 countsByYear W28919293622019 @default.
• W2891929362 crossrefType "journal-article" @default.
• W2891929362 hasAuthorship W2891929362A5006074198 @default.
• W2891929362 hasAuthorship W2891929362A5013226419 @default.
• W2891929362 hasAuthorship W2891929362A5015707436 @default.
• W2891929362 hasAuthorship W2891929362A5020559697 @default.
• W2891929362 hasAuthorship W2891929362A5020672869 @default.
• W2891929362 hasAuthorship W2891929362A5030970489 @default.
• W2891929362 hasAuthorship W2891929362A5040082039 @default.
• W2891929362 hasAuthorship W2891929362A5040210154 @default.
• W2891929362 hasAuthorship W2891929362A5042202815 @default.
• W2891929362 hasAuthorship W2891929362A5044250695 @default.
• W2891929362 hasAuthorship W2891929362A5049143229 @default.
• W2891929362 hasAuthorship W2891929362A5050031420 @default.
• W2891929362 hasAuthorship W2891929362A5050932223 @default.
• W2891929362 hasAuthorship W2891929362A5053190653 @default.
• W2891929362 hasAuthorship W2891929362A5060949051 @default.
• W2891929362 hasAuthorship W2891929362A5080548972 @default.
• W2891929362 hasAuthorship W2891929362A5081736939 @default.
• W2891929362 hasAuthorship W2891929362A5082287639 @default.
• W2891929362 hasAuthorship W2891929362A5085410610 @default.
• W2891929362 hasAuthorship W2891929362A5086705074 @default.
• W2891929362 hasConcept C121608353 @default.
• W2891929362 hasConcept C126322002 @default.
• W2891929362 hasConcept C141071460 @default.
• W2891929362 hasConcept C142724271 @default.
• W2891929362 hasConcept C143998085 @default.
• W2891929362 hasConcept C197934379 @default.
• W2891929362 hasConcept C203092338 @default.
• W2891929362 hasConcept C2776694085 @default.
• W2891929362 hasConcept C2778256501 @default.
• W2891929362 hasConcept C2778375690 @default.
• W2891929362 hasConcept C2778439243 @default.
• W2891929362 hasConcept C2778822529 @default.
• W2891929362 hasConcept C2779134260 @default.
• W2891929362 hasConcept C2779490328 @default.
• W2891929362 hasConcept C2780739268 @default.
• W2891929362 hasConcept C535046627 @default.
• W2891929362 hasConcept C71924100 @default.
• W2891929362 hasConceptScore W2891929362C121608353 @default.
• W2891929362 hasConceptScore W2891929362C126322002 @default.
• W2891929362 hasConceptScore W2891929362C141071460 @default.
• W2891929362 hasConceptScore W2891929362C142724271 @default.
• W2891929362 hasConceptScore W2891929362C143998085 @default.
• W2891929362 hasConceptScore W2891929362C197934379 @default.
• W2891929362 hasConceptScore W2891929362C203092338 @default.
• W2891929362 hasConceptScore W2891929362C2776694085 @default.
• W2891929362 hasConceptScore W2891929362C2778256501 @default.
• W2891929362 hasConceptScore W2891929362C2778375690 @default.
• W2891929362 hasConceptScore W2891929362C2778439243 @default.
• W2891929362 hasConceptScore W2891929362C2778822529 @default.
• W2891929362 hasConceptScore W2891929362C2779134260 @default.
• W2891929362 hasConceptScore W2891929362C2779490328 @default.
• W2891929362 hasConceptScore W2891929362C2780739268 @default.
• W2891929362 hasConceptScore W2891929362C535046627 @default.
• W2891929362 hasConceptScore W2891929362C71924100 @default.
• W2891929362 hasIssue "15_suppl" @default.
• W2891929362 hasLocation W28919293621 @default.
• W2891929362 hasOpenAccess W2891929362 @default.
• W2891929362 hasPrimaryLocation W28919293621 @default.
• W2891929362 hasRelatedWork W1919017214 @default.
• W2891929362 hasRelatedWork W2052076354 @default.
• W2891929362 hasRelatedWork W2088950395 @default.
• W2891929362 hasRelatedWork W2111879300 @default.
• W2891929362 hasRelatedWork W2119565846 @default.
• W2891929362 hasRelatedWork W2620160838 @default.

• next